News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 18, 2024

Closing Thoughts on the Current Ovarian Cancer Treatment Landscape

Ronald D. Alvarez, MD, MBA, provides closing commentary on the current ovarian cancer treatment landscape and the promising outlook over the next 20 years.

Episodes in this series

EP. 1 NCCN Guidelines Update Adds Mirvetuximab Soravtansine Plus Bevacizumab for FRα-Expressing, Platinum-Sensitive Ovarian Cancer

EP. 1 NCCN Guidelines Update Adds Mirvetuximab Soravtansine Plus Bevacizumab for FRα-Expressing, Platinum-Sensitive Ovarian Cancer

Video 1 - "NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer"

EP. 2 NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer

Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"

EP. 3 Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer

Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"

EP. 4 MIRASOL trial and DESTINY-PanTumor02 Trial Overview

Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"

EP. 5 Tailored Therapy: Decision Making for Ovarian Cancer Treatment

Video 5 - "Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment"

EP. 6 Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment

Video 6 - "Closing Thoughts on the Current Ovarian Cancer Treatment Landscape"

EP. 7 Closing Thoughts on the Current Ovarian Cancer Treatment Landscape

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Man clutching his stomach. | Image credit: @Shisuka_AdobeStock.jpeg

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

BySabrina McCrear

July 31st 2026

Peptide vial | Image credit: Iurii - stock.adobe.com

FDA Panel Backs 6 Peptides for Compounding

ByPearl Steinzor

July 31st 2026

Hepatitis B vaccine | Image Credit: angellodeco - stock.adobe.com

Childhood Hepatitis B Vaccination Tied to Lower Coinfection in Patients With HIV

ByBrooke McCormick

July 31st 2026

CLL image | Image Credit: © Momius-stock.adobe.com

Acalabrutinib May Weaken Rituximab’s Efficacy in CLL

ByMaggie L. Shaw

July 31st 2026

Colonoscopy | Image Credit: © MKPhoto-stock.adobe.com

Water Exchange Colonoscopy Raises Adenoma Detection Rate

ByMaggie L. Shaw

July 31st 2026

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access